{{Rsnum
|rsid=1032419
|Chromosome=6
|position=52970044
|Orientation=minus
|GMAF=0.2378
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 69.9 | 26.5 | 3.5
| HCB | 68.6 | 29.9 | 1.5
| JPT | 83.2 | 16.8 | 0.0
| YRI | 38.4 | 49.3 | 12.3
| ASW | 38.6 | 50.9 | 10.5
| CHB | 68.6 | 29.9 | 1.5
| CHD | 78.0 | 22.0 | 0.0
| GIH | 59.4 | 36.6 | 4.0
| LWK | 28.2 | 52.7 | 19.1
| MEX | 32.8 | 58.6 | 8.6
| MKK | 25.8 | 48.4 | 25.8
| TSI | 70.6 | 25.5 | 3.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1032419
|Name_s=rs1032419 A/G GSTA4
|Gene_s=-
|Feature=
|Evidence=PubMed ID:20157331
|Annotation=Risk or phenotype-associated allele: Not specified. Phenotype: This SNP was associated with clearance of docetaxel. Study size: 31. Study population/ethnicity: Patients with Non-Small-Cell Lung Carcinoma. Significance metric(s): p = 0.1495 (ANOVA); p = 0.2805 (QMIS); p = 0.0126 (KW) Type of association: PK.
|Drugs=docetaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291803
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1032419
|overall_frequency_n=37
|overall_frequency_d=126
|overall_frequency=0.293651
|n_genomes=26
|n_genomes_annotated=0
|n_haplomes=33
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}